Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$42.87B-12.92%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Philipp Navratil
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Employees
- 271,000
- Beta
- 0.50
- Country
- CH
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.88
Financials
Revenue
$42.87B-12.9%Net Income
$3.45B-24.9%EBITDA
$8.72B+5.2%Free Cash Flow
$3.55B+4.7%EPS (diluted)
$1.34+12.6%Shares Outstanding (diluted)
2.57B-33.8%Operating Expenses
$13.03BCash & Debt
$6.10BReturn of Capital
$7.98BDividend per Share
$3.97Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $89.53B | $9.04B | $3.51 |
| 2024 | $91.72B | $10.88B | $4.19 |
| 2023 | $93.35B | $11.21B | $4.23 |
| 2022 | $94.78B | $9.27B | $3.42 |
| 2021 | $87.47B | $16.91B | $6.06 |
| 2020 | $84.68B | $12.23B | $4.30 |
| 2019 | $92.86B | $12.61B | $4.30 |
| 2018 | $91.75B | $10.13B | $3.36 |
| 2017 | $90.12B | $7.16B | $2.31 |
| 2016 | $89.79B | $8.53B | $2.76 |
| 2015 | $89.08B | $9.07B | $2.90 |
| 2014 | $91.86B | $14.46B | $4.54 |
| 2013 | $92.37B | $10.02B | $3.14 |
| 2012 | $92.32B | $10.23B | $3.21 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NSRGF's reported EPS growth of 0.7% a year over 13 years.
- EPS in 5 years
- $3.64
- Implied price
- $83.65
- Return from $90.27
- -1.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $41.59 — -53.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 20 | 23 | 26 | 29 |
|---|---|---|---|---|---|
| -9.3% | -16.5% | -13.7% | -11.3% | -9.1% | -7.1% |
| -4.3% | -11.9% | -9.0% | -6.4% | -4.1% | -2.0% |
| 0.7% | -7.3% | -4.2% | -1.5% | 0.9% | 3.2% |
| 5.7% | -2.7% | 0.5% | 3.4% | 5.9% | 8.3% |
| 10.7% | 1.9% | 5.3% | 8.3% | 11.0% | 13.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-62.96%Social Signal Score
Mentions (11)
- Newsbusinessinsider.com·5d ago·Neutral
Nestlé's CEO says these 3 qualities will get you promoted Philipp Navratil started at Nestlé in 2001 and worked his way up to become CEO in 2025. He said workers who get promoted typically have three traits, the first being curiosity.
View source ↗ - Newsreuters.com·14d ago·Neutral
Nestle Russia pledges to continue operations despite Kremlin transfer of assets Nestle's Russian subsidiary pledged to continue its operations in Russia without regard to a decision by the Kremlin to transfer control of the company's assets, the Swiss food giant was quoted as saying on Monday.
View source ↗ - Newsreuters.com·18d ago·Neutral
Explainer: What we know about Russia's move to take control of Nestle, Auchan assets Swiss food giant Nestle and French retailer Auchan are scrambling to respond after Russian President Vladimir Putin placed their local businesses under temporary administration, a move that could pave the way for the assets to be seized.
View source ↗ - Newsreuters.com·18d ago·Neutral
Nestle responds to Putin's decision to put its Russian business under external administration Nestle on Friday responded to the Kremlin's decision to take control of the Swiss food maker's business in Russia, saying it was assessing its options.
View source ↗ - Newsseekingalpha.com·32d ago·Neutral
Nestlé: Fuel For Growth Is Working, But The Stock Is Fairly Valued Nestlé is reiterated at Hold, with valuation reflecting balanced risk-reward and limited margin of safety amid macro headwinds. NSRGY delivered resilient Q2 organic growth of 3.6%, strong emerging market performance, and advanced its Fuel for Growth cost savings and portfolio rebalancing. Portfolio reshaping continues with divestitures and targeted investments in premium, science-led segments, while free cash flow covers a 4.09%
View source ↗ - Newsreuters.com·33d ago·Neutral
Nestle to build infant formula plant in Brazil as part of $393 million investment Nestle will invest 2 billion reais ($392.73 million) in its nutrition and health division in Brazil through 2028, including 600 million reais for a new infant formula factory in Minas Gerais state, the company said on Thursday.
View source ↗ - Newswsj.com·34d ago·Negative
Nestle Inks $1 Billion Deal to Sell Health-Supplements Brands to Private Equity Firm Nestle will sell its mainstream vitamins, supplements and minerals business to Yellow Wood Partners, the latest move to tighten its portfolio and focus on core categories.
View source ↗ - Newsreuters.com·34d ago·Neutral
Nestle to divest mainstream supplements business for $1 billion Nestle said on Tuesday it has agreed to divest its mainstream vitamins, minerals and supplements business to U.S.-based Yellow Wood Partners for $1 billion.
View source ↗ - Newsreuters.com·40d ago·Negative
Nestle wants India to consult on food-labelling rules amid debate on packaging warnings Nestle wants India to consult with companies when drafting rules for front-of-pack health labelling on food and drinks to ensure it is done "scientifically," its chief executive said, amid a public debate on the lack of such measures in the country.
View source ↗ - Newsreuters.com·50d ago·Neutral
Russian company asks Putin to place Nestle assets under temporary administration, Kommersant reports A little-known Russian company has asked President Vladimir Putin to place the Russian assets of Swiss food group Nestle under temporary administration, the Kommersant newspaper reported on Monday, citing a source familiar with the matter.
View source ↗ - Newsreuters.com·50d ago·Negative
Focus: Nestle looks to develop new products to serve users of weight-loss drugs Nestle is seeking to turn the rise of GLP-1 weight-loss drugs from a threat into a business opportunity, using artificial intelligence and nutritional science to develop products aimed at millions of consumers taking medicines such as Ozempic and Wegovy.
View source ↗
Earnings
Thu, Feb 18(in 5 months)
Consensus estimate $2.85 per share
Typical surprise +4.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 23$2.75 vs $2.56beat
- Thu, Feb 19$2.71 vs $2.55beat
- Thu, Jul 24$2.48 vs $2.68miss
- Thu, Feb 13$2.59 vs $2.44beat
- Thu, Jul 25$2.79 vs $2.66beat
- Thu, Feb 22$2.74 vs $3.04miss
Estimates and results for NSRGF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in NSRGF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.